Hydroxyzine hydrochloride
Brand names: Atarax, Ucerax
Hydroxyzine hydrochloride is a sedating first-generation (piperazine) antihistamine used in psychiatry for short-term anxiety and for pruritus, also exploiting its sedative properties.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It antagonises central and peripheral histamine H1 receptors, producing sedative, anxiolytic and antipruritic effects, with additional antimuscarinic activity.
Prescribing in practice
- Hydroxyzine prolongs the QT interval and is contraindicated where there is known prolongation or significant risk factors, so avoid in cardiac risk, use the lowest effective dose for the shortest time, and avoid other QT-prolonging drugs.
- Its antimuscarinic and sedative effects warrant caution in the elderly, in urinary retention, glaucoma and prostatic enlargement.
- It potentiates alcohol and other central nervous system depressants and can impair driving and skilled tasks.
Monitoring
Monitor for excessive sedation, antimuscarinic effects and, where cardiac risk exists, QT-related concerns, with attention to the elderly.
Counselling the patient
- Expect drowsiness and avoid driving or operating machinery if affected.
- Avoid alcohol while taking this medicine.
- Report palpitations or fainting, and use only for the short term as advised.
Evidence & guidelines
MHRA guidance restricting hydroxyzine to the lowest effective dose and shortest duration reflects its recognised risk of QT prolongation.
Reference: MHRA Drug Safety Update; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185